Britain and America have secured a major bilateral deal that will guarantee no duties on British drug shipments going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the public health system. This move guarantees that tariffs on these crucial goods will be held at nothing for a timeframe of three years.
This deal is in response to recent statements to significantly raise import taxes on patented drug products, with potential rates discussed up to double the cost.
"This deal with the UK reinforces the global environment for new treatments and introduces much-needed equity to American-British drug exports," an announcement noted.
Economic Importance
Medicines are one of the UK's most significant exports to the America, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures show that in the one-year period to the end of the third quarter, the UK exported medicines worth billions to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement secures employment, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact includes several notable commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Last year, repayments exceeded twenty percent.
Industry Background
This agreement follows a ongoing row between the drug companies and the British authorities over medicine costs and NHS adoption.
The disagreement were heightened by arguments that US consumers were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while major funding commitments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.
